ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

VIGL Vigil Neuroscience Inc

3,03
0,29 (10,58%)
Nach Börsenschluss
Zuletzt aktualisiert: 22:46:47
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Vigil Neuroscience Inc VIGL NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,29 10,58% 3,03 22:46:47
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
2,72 2,67 3,05 3,03 2,74
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
17.4.202422:05GLOBEVigil Presents Key Findings from ILLUMINATE & IGNITE Studies..
26.3.202412:05GLOBEVigil Neuroscience Reports Fourth Quarter and Full Year 2023..
20.3.202412:05GLOBEVigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief..
13.3.202412:05GLOBEVigil Announces Upcoming Presentations at 2024 American..
12.3.202412:05GLOBEVigil Neuroscience to Present at Stifel 2024 Virtual CNS..
06.3.202422:25GLOBEVigil Announces Oral Presentation on Small Molecule TREM2..
02.3.202400:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.3.202423:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.2.202422:05GLOBEVigil Presents Poster on Impacts of Misdiagnosis and Genetic..
14.2.202417:33EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07.2.202422:05GLOBEVigil Neuroscience to Present at Guggenheim 6th Annual..
11.1.202416:30EDGAR2Form 8-K - Current report
03.1.202422:30GLOBEVigil Neuroscience Provides 2023 Year-in-Review and..
22.11.202322:05GLOBEVigil Neuroscience to Present at Evercore ISI 6th Annual..
16.11.202322:31EDGAR2Form 8-K - Current report
16.11.202322:05GLOBEVigil Neuroscience Reports Positive Interim Data from Phase..
07.11.202313:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07.11.202313:15EDGAR2Form 8-K - Current report
07.11.202313:05GLOBEVigil Neuroscience Reports Third Quarter 2023 Financial..
17.10.202313:05GLOBEVigil Neuroscience Announces First Participant Dosed in..
12.10.202322:06EDGAR2Form 8-K - Current report
05.10.202322:01GLOBEVigil Neuroscience to Present at Jefferies Inaugural Biotech..
26.9.202313:05GLOBEVigil Neuroscience Receives Positive Opinion from European..
13.9.202313:31EDGAR2Form 8-K - Current report
11.9.202318:00GLOBEVigil Neuroscience Presents VGL101 Complete Phase 1 Data and..
08.9.202322:10EDGAR2Form 8-K - Current report
08.9.202322:05GLOBEVigil Neuroscience Announces Update on its Small Molecule..
08.9.202313:05GLOBEVigil Neuroscience to Present at 2023 Morgan Stanley Global..
08.8.202313:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.8.202313:19EDGAR2Form 8-K - Current report
08.8.202313:05GLOBEVigil Neuroscience Reports Second Quarter 2023 Financial..
08.8.202300:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.8.202300:38EDGAR2Form 3 - Initial statement of beneficial ownership of..
07.8.202322:05GLOBEVigil Neuroscience Appoints Christopher J. Silber, M.D. as..
01.6.202313:00GLOBEVigil Neuroscience to Present at 2023 Jefferies Global..
10.5.202313:00GLOBEVigil Neuroscience Reports First Quarter 2023 Financial..
09.5.202313:00GLOBEVigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D...
08.5.202313:08GLOBEVigil Neuroscience Launches ALSPAware to Provide Access to..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock